Krystal Biotech Outlines Non-GAAP Operating Expenses for 2026 Amid International Expansion of VYJUVEK
Krystal Biotech (NASDAQ: KRYS) has outlined a non-GAAP operating expense range of $175 million to $195 million for the year 2026. During its Q2 earnings call, CEO Krish Krishnan highlighted continued U.S. demand and progress in international market expansion efforts. The company is advancing pricing and reimbursement discussions with key European markets including Germany, France, Italy, Spain, and the United Kingdom as part of its strategy to expand VYJUVEK overseas. Management emphasized a focus on execution during Q2 2026 while preparing for broader international adoption.
Tickers: $KRYS